|Videos|February 19, 2015
Toxicities Associated With CAR-Modified T Cell Therapy
Author(s)Jae Park, MD
Jae Park, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses toxicities associated with CAR-modified T cell therapy.
Clinical Pearls
Jae Park, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses toxicities associated with CAR-modified T cell therapy.
- There are unique toxicities associated with CAR-modified T cell therapy, such as cytokine release syndrome.
- Cytokine release syndrome can cause a patient to experience fever, low blood pressure, and breathing problems.
- There are now ways for a physician to predict the occurrence and severity of cytokine release syndrome.
- IL-6 receptor inhibitors or steroids can effectively manage cytokine release syndrome.
Related Content
Advertisement
